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BACKGROUND: Human platelet antigens (HPAs) are
polymorphisms in platelet membrane glycoproteins
(GPs) that can stimulate production of alloantibodies
once exposed to foreign platelets (PLTs) with different
HPAs. These antibodies can cause neonatal alloim-
mune thrombocytopenia, posttransfusion purpura, and
PLT transfusion refractoriness. Most HPAs are localized
on the main PLT receptors: 1) integrin aIIbb3, known as
the ﬁbrinogen receptor; 2) the GPIb-IX-V complex that
functions as the receptor for von Willebrand factor; and
3) integrin a2b1, which functions as the collagen
receptor.
STUDY DESIGN AND METHODS: We analyzed the
structural location and the evolutionary conservation of
the residues associated with the HPAs to characterize
the features that induce immunologic responses but do
not cause inherited diseases.
RESULTS: We found that all HPAs reside in positions
located on the protein surface, apart from the ligand-
binding site, and are evolutionary variable.
CONCLUSION: Disease-causing mutations often reside
in highly conserved and buried positions. In contrast,
the HPAs affect residues on the protein surface that
were not conserved throughout evolution; this explains
their naive effect on the protein function. Nonetheless,
the HPAs involve substitutions of solvent-exposed posi-
tions that lead to altered interfaces on the surface of
the protein and might present epitopes foreign to the
immune system.
P
olymorphisms in platelet (PLT) membrane gly-
coproteins (GPs) are responsible for alloanti-
body production upon exposure to PLTs with
different human PLT antigens (HPA).These anti-
bodies can cause neonatal alloimmune thrombocytope-
nia (NAIT), posttransfusion purpura, or PLT transfusion
refractoriness after exposure to unmatched PLTs. The
molecular basis of the 24 serologically deﬁned antigens
had been resolved1 and found to be a single-nucleotide
polymorphism (SNP) resulting in an amino acid substitu-
tion in 23 of 24 antigens: 12 HPAs are grouped in six bial-
lelicsystems(HPA-1to-5and-15)inwhichalloantibodies
against both the common (designated a) and the rare
(designated b) alleles were observed. For the rest, only
ABBREVIATIONS:bTD =b -tail domain; BSS = Bernard-
Soulier syndrome; EGF = epidermal growth factor; GP(s) =
glycoprotein(s); GT = Glanzmann thrombasthenia; HPA(s) =
human platelet antigen(s); LIBS = ligand-induced binding site;
LRR = leucine-rich repeat; MSA = multiple sequence alignment;
NAIT = neonatal alloimmune thrombocytopenia; PLT = platelet;
PSI = plexins, semaphorins, and integrins; SASA = solvent-
accessible surface area; SNP = single-nucleotide polymorphism.
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558 TRANSFUSION Volume 51, March 2011alloantibodies against the rare allele have been detected.
The only non-SNP is HPA-14bw, an in-frame triplet dele-
tioncodingforoneaminoacid(b3-Lys611).2Overall,there
are 17 different HPAs. A nomenclature was devised by the
International Society of Blood Transfusion and the Inter-
national Society of Thrombosis and Haemostasis (see
Table 1).
Most HPAs are localized to the main PLT receptors,
namely, integrin aIIbb3 that is also known as the ﬁbrino-
gen receptor, the complex GPIb-IX-V that functions as the
receptor for von Willebrand factor (VWF) and integrin
a2b1—the collagen receptor. Exceptional is HPA-15,
which is carried by the glycosylphosphatidylinositol-
linked protein CD1093 that was found to be a part of the
transforming growth factor (TGF)-b receptor system and
functions as a negative regulator of its signaling.4
Integrins are adhesion receptors that mediate vital
bidirectional signals within the cell.5 They form het-
erodimers of an a and a b subunit, bothType I membrane
proteins with large extracellular segments.6,7 There are 24
known heterodimers in mammals, composed of 18 a and
eight b subunits.5 The NH2-terminal ectodomain of the
a and b subunits assembles into an ovoid “head” and two
“legs” composed of several domains. The remaining seg-
ments form two tails that span the plasma membrane.6,7
Integrinb3subunitisknownasPLTmembraneGPIIIa
that forms heterodimers with aIIb and av integrins
subunits; aIIbb3 is the most abundant PLT receptor with
approximately 80,000 copies per PLT. The structure of the
inactive extracellular region of avb3 was the ﬁrst one
reported (PDB ID 1JV27). The structure of the entire
ectodomainofaIIbb3wasdeterminedintheinactivecon-
formation (PDB ID 3FCS8). The active conformation of
aIIbb3 was determined only for part of the ectodomain
(e.g., PDB ID 1TXV6,9 and 3FCU8). For the structural analy-
ses, we used the crystal structures relevant to each of the
HPAs.
ElevenHPAsarelocatedonthemostabundantrecep-
tor on PLTs surface: integrin aIIbb3. Nine of the HPAs are
mapped to the b3 subunit that was found to be the most
polymorphic GP on the PLT membrane.10 Some of the
HPAs are frequent in the Caucasian population (HPA-3
and HPA-15) but most of them are rare and some
are private polymorphisms, restricted to one family
TABLE 1. Data of the HPAs
HPA (frequency*) Gene SNP
Amino
acid Domain
Residue’s
SASA
Secondary
structure
Evolutionary
conservation
1 (0.15) b3 176 T>C Leu33Pro
Leu33Val
PSI 98% (3FCS) Loop 1 = variable
175 C>G 100% (3FCU)
2 (0.07) GPIba 482 C>T Thr145Met LRR 67% (1SQ0) Loop 3 = variable
3 (0.39) aIIb 2621 T>G Ile843Ser Calf2 Disordered region
(3FCS)
Loop 2 = variable
4 (0.01†) b3 506 G>A Arg143Gln b A 62% (1JV2) a-Helix 2 = variable
43% (1TXV)
76% (3FCS)
43% (3FCU)
5 (0.11) a2 1600 G>A Lys505Glu b-Propeller 73% in model Loop 1 = variable
6( <0.01) b3 1544 G>A Arg489Gln EGF-1 76% (3FCS) 1 = variable
7( <0.01) b3 1297 C>G Pro407Ala Hybrid 27% (1JV2) Loop 6 = intermediate
17% (1TXV)
8% (3FCS)
8( <0.01) b3 1984 C>T Arg636Cys bTD 59% (1JV2) Loop 1 = variable
66% (3FCS)
9( <0.01) aIIb 2602 G>A Val837Met Calf2 40% (3FCS) Loop 6 = intermediate
10 (<0.01) b3 263 G>A Arg62Gln Hybrid 32% (1JV2) b-Sheet 1 = variable
63% (1TXV)
71% (3FCS)
69% (3FCU)
11 (<0.01) b3 1976 G>A Arg633His bTD 17% (1JV2) Loop 1 = variable
53% (3FCS)
12 (<0.01) GPIb b 119 G>A Gly15Glu No structure 2 = variable
13 (<0.01) a2 2483 C>T Thr799Met Calf1 32% in the model b-Sheet 6 = intermediate
14 (<0.01) b3 1909-11 del Lys611del bTD 15% (1JV2) a-Helix 4 = variable
41% (3FCS)
15 (0.49) CD109 2108 C>A Tyr703Ser No structure 4 = variable
16 (<0.01) b3 497 C>T Thr140Ile bA 51% (1JV2) a-Helix 1 = variable
31% (1TXV)
55% (3FCS)
60% (3FCU)
17 (<0.01) a2 3389 C>T Thr1087Met Calf2 53 % in the model b-Sheet 5 = intermediate
* The frequency of the rare allele in Europeans is given in parentheses.
† The frequency of the rare allele in an Asian person.
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gen most commonly implicated in alloantibodies produc-
tion is HPA-1a, a Leu33Pro substitution in integrin b3.
Approximately80%ofNAITcasesarecausedbyanti-HPA-
1a. The second frequent antigen causing NAIT is HPA-5b
(10%-15% of NAIT cases), while all the rest cause NAIT
very rarely.11 Only 10% of HPA-1b–homozygous women
with an HPA-1a–positive fetus develop anti-HPA-1a
alloantibodies during pregnancy.12 Maternal responsive-
ness to HPA-1a shows strong association with DRB*0101
allele encoding human histocompatibility leukocyte
antigen DR52a. It was shown that short peptide contain-
ing HPA-1a (Leu33) bind to recombinant DR52a mol-
ecules, whereas the HPA-1b (Pro33) version does not.
Interestingly, although most HPAs are nonsynony-
mous SNPs and HPA-14w is even a single-amino-acid
deletion,theyprobablyinﬂictaminoreffectonPLTrecep-
tors function since they do not cause inherited diseases,
and even their inﬂuence on thrombus formation is con-
troversial.13 The major complication is their involvement
in immunogenic response.
In this article we analyzed the structural features and
evolutionary conservation of the HPAs to deﬁne the char-
acteristics that lead to immunologic problems but not to
inherited disease. We demonstrate that all HPAs studied
here involve residues located on the surface of the protein
far from the ligand-binding site and are not evolutionary
conserved. These criteria imply that the substitutions in
thesepositionspresentaminoreffectonthestructureand
function of the protein and therefore, do not represent
disease-causing mutations. Moreover, their location on
the surface suggests that they could play a role in present-
ing epitopes.
MATERIALS AND METHODS
Evolutionary conservation analyses
The evolutionary conservation analyses were calculated
using the Bayesian method14 implemented in the ConSurf
Web server (http://consurf.tau.ac.il)15 or the ConSeq
Web server (http://conseq.tau.ac.il/).16 The conservation
scores range from 1 to 9, indicating variable-to-conserved
positions.
a-Integrins
A multiple sequence alignment (MSA) of the b-propeller
domain in various a-integrins was constructed as
described previously.17 This alignment was used to calcu-
late the conservation scores for the HPAs in the
b-propeller domain of a2. An MSA of the thigh and calf
domains was taken from the a-integrin family in the Pfam
database (http://pfam.sanger.ac.uk/).This alignment cor-
responds to Residues 481 to 921 in aIIb and was used to
calculate the conservation scores for the HPAs in the calf
domain of aIIb. The last two strands of the calf2 domain
constitute a very variable region among a-integrins and
therefore were not included in the Pfam alignment. Since
one of the HPAs in a2 is located on the C-terminus of the
calf2 domain, we generated a smaller MSA via ConSeq,
using a2 human as the query sequence to collect 50
homologs from the Swiss-Prot database18 that were
aligned using MUSCLE.19 We note that the conservation
scores for HPA-13 located in calf1 were identical when
using in the Pfam and ConSurf generated alignment.
b-Integrin
Human b3 (Swiss-Prot entry ITB3_HUMAN) was used as
query to collect homologous sequences from the Swiss-
Prot database18 using PSI-BLAST.20 The resulted 27
sequences were aligned using CLUSTALW21 with default
parameters. This intermediate alignment was used to
generate a hidden Markov model,22 which was subse-
quently utilized to collect remote homologous sequences
from the UniProt database23 that were aligned using
MUSCLE.19 From the 105 hits found, redundant (above
95% sequence identity) and fragmented sequences, as
well as sequence variants and mutants, were discarded
along with sequences that included irregular characters
or ones that were sequenced by the whole genome
shotgun project therefore considered as preliminary
data. The resulted alignment contained 66 b-integrins
and was used to calculate the evolutionary conservation
scores in b-integrins. To support the analysis, we also
used an alignment generated by ConSurf using 300
homologous sequences collected from the UniProt data-
base23 and aligned using MUSCLE.19 The conservation
scores were very similar.
Leucine-rich repeat family of proteins
Human GPIba (PDB ID 1SQ0, Chain B)24 was used as
query to calculate the evolutionary conservation scores
via the ConSurfWeb server.15 The calculations were based
on an MSA constructed from 200 homologous sequences
from the Swiss-Prot database18 collected using PSI-BLAST
and aligned with MUSCLE.19 Since the structure of human
GPIbb (Swiss-Prot entry: GP1BB_HUMAN) is not avail-
able, we used the ConSeq Web server16 to calculate the
evolutionary conservation scores using 90 sequences col-
lected from the Swiss-Prot database with PSI-BLAST20 and
aligned by MUSCLE.19
CD109
Since the structure of human CD109 is not available
(Swiss-Prot entry: CD109_HUMAN), the ConSeq Web
server16 was used to calculate the conservation scores of
human CD109 based on 66 sequences collected from the
Swiss-Prot database18 using PSI-BLAST20 and aligned by
MUSCLE.19
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The analyses were based on the crystal structures of aVb3
(PDB ID 1JV2),7 aIIbb3( P D BI D1 T X V , 6,9 3FCS,8 and
3FCU),8 and GPIba (PDB ID 1SQ0).24 The structure of a2
was modeled based on the crystal structure of aIIbb3
(PDB ID 3FCS8) using NESTs25 with default parameters.
The alignment between aIIb and a2 was derived from an
MSA of 50 homologs sequences of a-integrins generated
by ConSurf as described above. The b-propeller domain,
lacking the I domain, was modeled separately using
an alignment with aIIb derived from an MSA of the
b-propeller domain of a-integrins constructed as
described previously.17
The solvent-accessible surface area (SASA) was calcu-
lated using the SURFV program with a probe sphere of
radius 1.4 Å and default parameters.26 The percentage of
the surface exposure of each residue in the monomer was
calculated from the total solvent-accessible area on a Gly-
X-Gly tripeptide (where X represents each of the 20 amino
acids).Weconsideraresiduetobeburiediflessthan5%of
its surface is accessible to the solvent.27 More importantly,
we examined the location of the residue in relation to the
surface of the protein.
Statistical analysis
Data are expressed as mean  standard deviation.
Kruskal-Wallis test was used to analyze the difference
between groups using computer software (GraphPad
PRISM5, GraphPad Software, Inc., San Diego, CA). A p
value of less than 0.05 was considered as a signiﬁcant dif-
ference. In case that the SASA was calculated in various
structures, the mean value was used for the statistical
analysis.
RESULTS
HPA polymorphisms in integrin b3
Integrin b3 ectodomain is composed of eight domains—
the plexins, semaphorins, and integrins (PSI); bA; hybrid;
four epidermal growth factor (EGF) domains; and a b-tail
domain (bTD).There are nine HPAs located in integrin b3;
seven of them (HPA-4, -7, -8, -10, -11, -14, and -16) are
visible in the inactive structures of both avb3 (PDB ID
1JV2)andaIIbb3(PDBID3FCS).Structuralanalysesofthe
crystal structures revealed that all HPAs are exposed to the
solvent(Table 1)and,moreover,arelocatedonthesurface
of the protein and thus do not play a role in the stabiliza-
tion of the protein fold.
Integrinactivationisamultistepprocessthatinvolves
transitions between multiple conformations.6 Corre-
spondingly, the heterodimer is highly ﬂexible. The avb3
and aIIbb3 crystal structures might have captures slightly
different conformations of the b3 that led to differences in
the solvent accessibility of the HPA-related residues
(Table 1).
Some HPAs are located close to the interface with
adjacent domains on the b subunit. For example, Arg633,
the polymorphic residue of HPA-11, and Arg636, the poly-
morphic residue of HPA-8, both located in the bTD, are
close to the hybrid domain. In the inactive complex aVb3,
Arg633 forms a salt bridge with Asp393 from the hybrid
domainandissurroundedbyLeu389,Gly388,andCys374.
In the structure of aIIbb3, also in the inactive conforma-
tion, there are some conformational variations with
respect to the inactive b3i nt h eaVb3 complex. In aIIbb3,
Arg633 is facing away from the hybrid domain, yet might
be still bound with Glu378 on the hybrid domain. Arg636
isincloseproximitytoMet387andGly388fromthehybrid
domain in the aIIbb3 complex, while in the aVb3 struc-
ture, Arg636 is close to Asn376. Arg489 of HPA-6, located
on the EGF-1 domain, is close to the Calf1 domain of the
aIIb subunit (in the inactive conformation) but is not in
direct contact.
Five polymorphic residues involved in the formation
ofHPA-1,-4,-7,-10,and-16arevisibleinthecrystalstruc-
tures of both the active (PDB IDs 3FCU8 or 1TXV6,9) and
the inactive (PDB ID 3FCS)8 conformations of integrin
aIIbb3, enabling analysis in both states. Different solvent
exposures of HPA-4 and -7 were detected due to structural
changes in the backbone between the two conformations,
as well as different rotamers (side-chain conformation;
Table 1). Nevertheless, in both states, all HPA-related resi-
dues were found to be located on the surface of the
protein, exposed to the solvent. Moreover, all of them are
located far away from the ligand binding site and are not
in direct contact with the a subunit in the structurally
determined conformations (Fig. 1A). Interestingly, Leu33
of the most immunogenic HPA-1a is totally exposed
(Table 1) and found on the tip of a loop connecting two
antiparallel b-sheets in the PSI domain. This loop is ﬂex-
ibleandparticularlylonginintegrins.6,7Theloop,andpar-
ticularly Leu33, is close to the EGF domains in the inactive
conformation (Fig. 1A).
Evolutionary conservation analysis of b-integrins
from different species revealed that most HPAs occupy
evolutionary variable positions (Table 1). Moreover, some
of the polymorphic residues (HPA-1b, -4b, -6b, -10b, and
-11b)canbefoundinthecorrespondingpositionsinother
b-integrins (Table 2 in bold), supporting the benign effect
of the amino acid substitutions on PLTs normal function.
The third allele in HPA-1 (Leu33Val) is a particularly naive
substitution that was also found in other b-integrins,
showing a conservative change, in an exposed location.
Interestingly, differences in reactivity of anti HPA-1a anti-
bodies were observed, some bind also to b3-Val33 while
others showed signiﬁcantly reduced reactivity.28
The residue related to HPA-7 (Pro407) is unique
among other HPAs because it shows an intermediate evo-
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Volume 51, March 2011 TRANSFUSION 561Fig. 1. Structural location of the HPA-related polymorphic residues. A cartoon representation of proteins involved in HPAs.The ori-
entation was picked to best display all HPA-related residues. Scale bar for the evolutionary conservation scores is displayed in the
middle. (A) HPAs at the integrin b3 subunit.The ectodomain of the aIIbb3 complex is presented at the inactive conformation (PDB
ID 3FCS
8).The b3 subunit is in a cartoon representation and aIIb is presented as a sand-colored ribbon. In the left panel, b3i s
colored according to the different domains—the PSI, bA, hybrid, EGF-1 to -2, EGF-3, EGF-4, and the bTD in orange, dark red, yellow,
cyan, blue, magenta, and green, respectively. In the right panel, b3 is colored according to evolutionary conservation scores calcu-
lated based on a set of 66 homolog sequences of b-integrins.The HPAs polymorphic residues located in b3 are presented as space-
ﬁlled atoms. It is clear that the HPAs are located on the surface of the protein and that they are all evolutionary variable. Also, all
HPAs are facing away from the interface with the a subunit, suggesting that the substitutions do not disturb the heterodimeric
interactions. (B) HPAs at the integrin aIIb subunit.The ectodomain of the aIIbb3 complex is presented at the inactive conforma-
tion (PDB ID 3FCS). aIIb is in a cartoon representation, colored according to the different domains—b-propeller, thigh, calf1, and
calf2 in purple, dark green, dark blue, and brown, respectively. b3 is presented as a gray-colored ribbon.Val837, associated with
HPA-9, is presented as space-ﬁlled atoms. It is clear that HPA-9 is located on the surface, far from the interface with the b subunit.
Ile843, associated with HPA-3, is located in a disordered region, illustrated with a black line, which could not be determined in the
structure. (C) HPAs at the integrin a2. A model of a2, without the I-domain, was built using aIIb as a template.The b-propeller
domain and the thigh and calf domains were built separately, to ensure the reliability of the alignment between a2a n daIIb. a2i s
in a cartoon representation, colored according to the different domains—b-propeller, thigh, calf1, and calf2 in purple, dark green,
dark blue, and brown, respectively.The HPAs located in a2 are presented as space-ﬁlled atoms. a2 is naturally interacting with the
b1 subunit.Taking into account that the a2b1 interactions are similar to the heterodimeric interactions within the aIIbb3 complex,
the b subunit is illustrated accordingly. All HPA polymorphic residues in a2 are located on the opposite side from the interface with
the b subunit. (D) HPAs at GPIba.The GPIba, in a complex withVWF (PDB ID 1SQ0), is shown in a cartoon representation.VWF
domain is sand-colored, while GPIba is colored according to evolutionary conservation scores.Thr145, associated with HPA-2, is
presented as space-ﬁlled atoms. It is clear that HPA-2 polymorphic residue is evolutionary variable, surface exposed, and located
far from the interface with the ligandVWF.
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occupied by a variety of amino acids and is not restricted
to proline in b-integrins from other species (Table 2).
Pro407 is located on a loop at the hybrid domain, facing
the solvent, and is not in close proximity to other domains
in the structurally determined conformation of integrin
b3. The substitution (Pro407Ala) probably has a minor
effect on the structure.
HPA-14, the single-deletion polymorphism,
Lys611del, is located within the bTD, at the C-terminus of
the ectodomain.The region encompassing Lys611 forms a
helix in the aVb3 structure; thus such a deletion might
disrupt the structure. However, this helix is partially
unwound in the aIIbb3 inactive conformation (PDB ID
3FCS) raising uncertainties about its stability and contri-
bution to the overall fold.
Recently, two additional low-frequency SNPs, not yet
approved as HPAs, were reported within integrin b3:
Lys137Gln and Glu628Lys.29 Both positions are highly evo-
lutionary variable and located on the surface of the
protein (Fig. 1A), consistent with the other HPAs.
HPA polymorphisms in integrin aIIb
Integrin aIIb (PLT membrane GPIIb) comprises the
b-propeller, thigh, and two calf domains. Two HPAs
(HPA-3 and -9) were found in the aIIb integrin. Both
related residues (Ile843 and Val837, respectively) are
located in the calf2 domain (Fig. 1B), within a highly evo-
lutionary variable region that shows many insertions and
deletions among a-integrins. This region is disordered in
the crystal structures, suggesting that it is ﬂexible. Val837
is visible in the inactive structure of aIIbb3.8 It is located
on a loop facing the solvent, far from the b subunit or
other domains in aIIb (Fig. 1B). Residues 840 to 873 are
missing in the crystal structure of aIIbb3 (due to the dis-
order of that region); thus we could not examine Ile843.
Recently, a low-frequency HPA
was found in aIIb corresponding to
Thr619Met substitution29 at the calf1
domain.AsobservedfortheotherHPAs,
this position is highly evolutionary vari-
able (ConSurf score = 1; see Materials
and Methods) and located on the
surface of the protein (Fig. 1B).
HPA polymorphisms in integrin a2
Integrina2(PLTmembraneGPIa)forms
hetrodimers with integrin b1 and, simi-
larly to the integrins discussed above, is
important for PLT function. Three poly-
morphic residues in the a2 integrin
form antigens, HPA-5, -13, and -17,
localized to the b-propeller, calf1, and
calf2 domains, respectively. Since the only crystal struc-
ture of a2 is for the I-domain in the b-propeller (PDB ID
1AOX30), we modeled the rest of the structure using aIIb
(PDB ID 3FCS)8 as a template.
The second common allele causing NAIT (HPA-5b),
affecting Lys505, is located on one of the loops of the
b-propeller domain, on the surface of the protein, far
from the interface with the b subunit (Fig. 1C). Lys505
corresponds to Arg355 in aIIb; this position, as well as
the surrounding residues on the loop, is evolutionary
variable (Table 1). The rare HPA-13b is related to the sub-
stitution of Thr799 located within a b-strand in the calf1
domain, facing the solvent (Fig. 1C). This position, which
corresponds to Asp636 in aIIb, shows intermediate con-
servation, yet is occupied by the polymorphic methion-
ine in other a-integrins, suggesting tolerance to such
substitution. HPA-17, affecting Thr1087, is located at the
C-terminus of the calf2 domain. Thr1087 shows interme-
diate conservation among the closest 50 sequences
homologous to the human a2 (Table 1), yet is located in
a region that is highly variable between a-integrins. Inte-
grin a2 forms a complex with b1. Taking into account
that the interactions between the a and b subunits
resemble those of aIIbb3 and aVb3, all three HPAs on a2
are located on the opposite side from the interface with
the b subunit.
HPA polymorphisms in the GPIb-V-IX complex
The GPIb-V-IX complex, another PLT receptor, is com-
posed of four Type I membrane spanning proteins that
belong to the leucine-rich repeat (LRR) family of proteins:
GPIba, GPIbb, GPIX, and GPV. HPA-2 and HPA-12 are
localized to the two ﬁrst GPs, respectively. Crystal struc-
tures are available only for the LRR domain of GPIba (e.g.,
PDB ID 1SQ0). HPA-2, affecting Thr145, is located in this
region, on the surface of the protein, facing the solvent. It
TABLE 2. Amino acid residues occupying the HPA-related positions
in b-integrins*
HPA Position
Common
allele
Rare
allele Residue variety in b-integrins
1 33 Leu Pro (Val) A, D, E, G, K, L,M ,N ,P,Q ,S ,T ,V,Y
4 143 Arg Gln A, E, G, K, N, Q, R,S ,T ,V
6 489 Arg Gln A, D, E, G, H, K, N, P, Q, R, S, T, V
7 407 Pro Ala D, E, H, I, K, L, P,Q ,R ,S ,T ,V
8 636 Arg Cys D, E, G, H, K, L, N, P, Q, R,S ,T ,Y
10 62 Arg Gln D, E, F, H, I, K, L, N, Q, R,S ,T ,V
11 633 Arg His A, D, E, G, H,K ,L ,N ,Q ,R,S ,T ,V
14 611 Lys del D, F, H, K,L ,N ,Q ,R ,S ,Y
16 140 Thr Ile A, D, E, G, K, L, N, Q, R, S, T,V
* The residue variety was gathered using the ConSurf server and was based on an
alignment of b subunit integrins. For each HPA-related position, the identity of the
amino acid in each of the 66 homolog sequences in the alignment was examined. A list
of all possible amino acid identities for the speciﬁc position is reported. The amino acid
identity occupying the positions in human b3 HPAs is in bold.
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(Fig. 2D).
The GPIb-V-IX complex is known to regulate throm-
bin function by distinct interactions.31 There are two
crystal structures of thrombin bound to GPIba (PDB IDs
1P8V32 and 1OOK31). The two structures present different
interpretations to how the two proteins interact.33 In one
of these structures (PDB ID 1P8V),32 Thr145 is located at
the interface with one of the thrombin molecules.
Recently a model of GPIbb ectodomain was constructed,
based on decorin crystal structure (PDB ID 1XKU34), but is
not yet available for analysis.35
HPA polymorphisms in CD109
CD109 antigen, also known as PLT-speciﬁc Gov antigen, is
aT G F - b1 binding protein for which no structure is avail-
able. The closest homolog with known structure has 26%
sequence identity, which is not enough for accurate struc-
tural modeling. Tyr703 (Residue 682 in the mature
protein), associated with HPA15, is evolutionary variable.
DISCUSSION
Polymorphisms versus disease-causing mutations
Most HPAs are localized to integrin aIIbb3, speciﬁcally
to the b3 subunit.10 Several missense mutations in this
integrin were reported to cause severe bleeding dis-
order named Glanzmann thrombasthenia (GT) (http://
sinaicentral.mssm.edu/intranet/research/glanzmann/
menu). Single-nucleotide sequence alterations res-
ponsible for both HPAs and GT result in nonsynonymous
amino acid substitutions. The interesting question is why
some amino acid substitutions cause disease while others
are naive polymorphisms.36,37 Moreover, some SNPs are
immunogenic, while others were not reported to cause an
immuneresponse.Ourworkinghypoth-
esisisthatmutationsinresiduesthatare
evolutionary conserved and are deeply
buried within the fold of the protein or
located near the active site, near the
ligand binding site or at the interfaces
with other domains, are most likely to
damagethestructureandfunctionofthe
protein. On the other hand, substitu-
tions in residues that are located on the
surfaceoftheproteinandareevolution-
ary variable will be more tolerable.
Having this in mind, we examined the
HPAsintermsofevolutionaryconserva-
tion and structural characteristics. In
comparison we analyzed mutations
causing GT or Bernard-Soulier syn-
drome (BSS) previously reported by us
(Table 3) and validated (by frequency
in any population) SNPs found in NCBI SNP data-
base that were not reported to cause an immune response
(Table 4).
OurstructuralanalysisrevealedthattheSNPsrespon-
sible for the HPAs affected nonconserved positions
located on the surface of the protein, far away from the
ligand binding site and not in direct contact with other
subunits. In contrast, disease-causing mutations within
integrins often disturb highly conserved and buried posi-
tions in the proteins’ cores38 (Table 4, Fig. 2), which imply
that they are essential for maintaining the basic structure
common to all integrins. Similarly, a missense mutation
leadingtoararebleedingdisorder,BSS,wasmappedtoan
evolutionary conserved and hydrophobic residue at the
core of the LRR region in the GPIb-IX-V complex.39 In con-
trast, Thr145 responsible for HPA-2, located at the same
repeat region (Fig. 1D), is exposed to the solvent and is
evolutionary variable. Consequently, we raised the ques-
tion whether immunogenicity of HPAs, as opposed to
SNPs not reported to cause an immune response, is the
consequence of the presence of evolutionary variable and
exposed residues in HPAs. Analyses of integrin aIIbb3
polymorphisms that were not published as immunogenic
showed that some polymorphic residues are evolutionary
variable and exposed similarly to HPAs, while others are
buried. Only one polymorphism was shown to be evolu-
tionary conserved, but not buried as found for missense
mutations (Table 4). Statistical analysis showed that HPAs
differed signiﬁcantly from causing disease missense
mutations in both variables: evolutionary conservation
and SASA (Fig. 2). In contrast, HPAs differed from nonim-
munogenic polymorphisms in SASA but not in their con-
servation score, suggesting that the immunogenicity is
dependent mostly on the structural location of the
residue. Interestingly, it was found that nonimmunogenic
polymorphisms differed signiﬁcantly from missense
Fig. 2. Characterization of HPAs, disease-causing missense mutations, and nonim-
munogenic SNPs. Conservation score (n = 17) and residue’s SASA (n = 14) of HPA-
related polymorphic residues (), missense mutations causing disease (n = 13, ),
and nonimmunogenic polymorphism (n = 8, ) presented as mean  SD. Signiﬁcant
differences marked as * p < 0.05 and ***p < 0.001.
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Taken together, we can conclude that although
disease-causingmutationsandSNPsresponsibleforHPAs
can be localized to the same domain, they differ in their
evolutionary conservation and solvent exposure. Interest-
ingly, although most HPAs result in substituting chemi-
cally dissimilar residues, they have no dramatic effects on
the apparent function of the proteins. The observations
that these positions are evolutionary variable and surface
exposed explain their tolerance to substitutions for resi-
dues of various properties. Actually, in most cases, the
amino acid of the polymorphic residue was found in
equivalent positions within homologous proteins
(Table 2). It is interesting to note that many of the HPA-
related positions are occupied by positively charged
TABLE 3. Analyses of nonsynonym polymorphisms in integrin aIIbb3 that have not been reported as
immunogenic antigens
Gene SNP
Amino
acid Domain
Residue’s
SASA Conservation score Database
b3 217 T>G Leu40Arg PSI 28.8% (3FCS) 4 = variable rs36080296
20.7% (3FCU)
b3 366 C>T Leu90Phe Hybrid 0.56% (3FCS) 6 = intermediate rs72547409
0.61% (3FCU
1.27% (1JV2)
b3 1377 G>A Val427Ile Hybrid 0% (3FCS) 6 = intermediate rs5921
0% (3FCU)
0% (1JV2)
b3 1980 G>A Glu628Lys bTD 66.5% (3FCS) 1 = variable rs70940817
45.6% (1JV2)
aIIb 440 C>G Leu116Val b-Propeller 34.9% (3FCS) 1 = variable
35.8% (3FCU
aIIb 1977 G>T Val618Leu Calf1 16.8% (3FCS) 1 = variable rs7207402
aIIb 2300 C>A Ser725Arg Calf1 11.6% (3FCS) 9 = conserved rs74563314
aIIb 2934 T>A Tyr937Asn Calf2 23.7% (3FCS) 4 = variable rs2934
TABLE 4. Disease-causing mutations
Gene
Missense
mutation Amino acid Domain Residue’s SASA
Conservation
score Disease Reference
b3 1157 T>G Cys13Gly PSI 0.3% (3FCS) 9 = conserved GT Peretz et al.
38
0.64% (3FCU)
b3 356 G>A Arg93Glu Hybrid 1.4% (3FCS) 9 = conserved GT Peretz et al.
38
1.4% (FCU)
14.5% (1JV2)
b3 428 T>G Leu117Trp bA 0% (3FCS) 9 = conserved GT Peretz et al.
38
0% (FCU)
0% (1JV2)
b3 652 C>T His192Tyr bA 4.3% (3FCS) 9 = conserved GT Peretz et al.
38
1.9% (FCU)
1.7% (1JV2)
b3 1261 G>A Val395Met Hybrid 3.7% (3FCS) 8 = conserved GT Peretz et al.
38
1.4% (FCU)
4.3% (1JV2)
b3 1723 T>C Cys549Arg EGF-3 13.97% (3FCS) 9 = conserved GT Mor-Cohen et al.
51
23.29% (1JV2)
aIIb 97 A>G Asn2Asp b-propeller 0.55% (3FCS) 9 = conserved GT Mansour et al.
52
4.93% (3FCU)
aIIb 416 C>T Ala108Val b-propeller 0% (3FCS) 8 = conserved GT Peretz et al.
38
0% (FCU)
aIIb 607 T>G Phe171Cys b-propeller 24.2% (3FCS)* 8 = conserved GT Rosenberg et al.
17
23.5% (FCU)*
1% in the complex
aIIb 886 G>A Gly265Arg b-propeller 0.1% (3FCS) 9 = conserved GT Peretz et al.
38
0% (FCU)
aIIb 1139 G>T Gly349Val b-propeller 8.5% (3FCS) 8 = conserved GT Peretz et al.
38
7.8% (FCU)
aIIb 2438 C>A His782Asn Calf-2 5.02% (3FCS) 6 = intermediate GT Losonczy et al.
53
GPIba 709 T>G Trp207Gly S-S loop 0% (1SQ0) 5 = intermediate BSS Rosenberg et al.
39
* F171 is on the interface with b3. In the structure of the heterodimer, F171 is only 1% exposed to the solvent.
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ofthesurfaceelectrostaticpotential.Thismightberelated
to the formation of unique interfaces that lead to antige-
nicity and to the production of antibodies. The antigenic-
ity of the polymorphisms seems to be dependent on the
amino acid residue, as shown for HPA-1. The immuniza-
tion against HPA-1a (Leu33) is known to be the most
common cause of NAIT (80%) while the HPA-1b allele
(Pro33) is responsible for only approximately 4% of NAIT
cases.This discrepancy in the frequencies is probably due
to a different antigenicity of the alleles, as shown by the
observation that peptides containing the Leu33 polymor-
phism bind to recombinant DR52a molecules, whereas
the Pro33 version does not.12 Similarly, HPA-5b allele is
immunogenic and the HPA-5a is not (10% in NAIT com-
pared to 0%). Although the likelihood of antigen incom-
patibility between mother and fetus is very high in HPA-3
andHPA-15systems,duetotheirhighheterozygosityrate,
they are less likely to cause NAIT compared to HPA-1 and
HPA-5 systems. Interestingly, HPA-1 and -5 are associated
withverylowevolutionaryconservation(1 = variable)and
very high residue SASA (Table 1).
Some HPAs are nonlinear epitopes
Leu33 involved in HPA-1 is located in a loop of the PSI
domain of integrin b3, totally exposed to the solvent in
both the active and the inactive conformations of aIIbb3
(Table 1). HPA-1 was shown to be a part of a nonlinear
epitope40 sensitive to disulﬁde bond reduction or cysteine
substitution in the PSI domain.41 This suggests that the
epitope is dependent on the intact tertiary structure of its
domain. Moreover, substitutions such as Arg93Gln or
Pro407Ala (of HPA-7), both localized to the hybrid
domain, were shown to be critical for binding of anti-
HPA-1a antibodies.42 This indicates that the HPA-1a
epitope is dependent on residues in the neighboring
hybrid domain. The sensitivity of the HPA-1a epitope to
polymorphisms located in neighboring region can explain
its heterogeneous nature as demonstrated by the third
allele Val33, which reacts with some anti-HPA-1a but not
withothers.12InadditiontoHPA-1,epitopesofotherHPAs
were also shown to be nonlinear43 and affect posttransla-
tionprocess:Forinstance,Arg636Cys(constructedHPA-8)
alters the N-linked glycosylation pattern44 and deletion of
Lys611 (HPA-14b) modiﬁes the disulﬁde bond pattern,
both mapped to the bTD of integrin b3. Similarly, HPA-3
determinant, caused by Ile843Ser substitution in integrin
aIIb, is dependent upon O-linked carbohydrate.45 The
dependency of the immune response on the glycosylation
statecanexplaintheheterogeneousnatureofthisepitope.
It has been shown that some anti-HPA-3a require sialic
acid or O-linked oligosaccharide residues for reactivity,
whereas others do not.45
Association between HPA epitopes and activation
states of integrins
Integrins such as aIIbb3 were shown to be in a bent inac-
tive conformation on the resting PLT. After physiologic
activation, the integrins shift to the extended active con-
formation leading to exposure of multiple new epitopes
namedLIBS(ligand-inducedbindingsite).6Theactivation
mechanism of the integrins involves multiconformations
of both subunits;6 few were recapitulated in the available
crystal structures.6-8 We found some differences in the
SASA of HPA-related residues in the various conforma-
tions of the b3 subunit due to structural changes in the
backbone as well as different rotamers (side-chain
conformation; Table 1). It is possible that structural
changes and rearrangements of interdomain orientation
accompanyingtheactivationprocessleadtoalterationsin
the presentation of the HPAs’ epitopes. Correspondingly,
some HPA-related residues are mapped to the same
regions harboring the LIBS epitopes that become exposed
on activation. For example, few LIBS epitopes, as well as
HPAs-1,-6,-8,-11,and-14ofb3integrin,arelocatedinthe
PSI, bTD, and EGF domains.8 Similarly, the epitopes for
HPA-3 and -9 at the aIIb integrin, as well as the epitope to
the LIBS antibody PMI-1,8,45 are mapped to the same
region—an unstructured loop in the calf2 domain of aIIb.
This loop is cleaved during biosynthesis, thus enabling
breathing movements that can shift the equilibrium
toward integrin extension.8 The antigenic determinant of
HPA-3 is similar to that of the LIBS antibody PMI-1, sug-
gesting that the activation state might also affect exposure
of the HPA-3 epitope.45
The rearrangements of interdomain orientation
during activation impinge on the presentation of the HPA
epitopes.Then again, some HPA polymorphisms can have
an effect on the dynamic of the conformational changes
involved in the activation process. For example, Arg633 in
b3, the residue substituted in HPA-11, was shown to be
important for constraining aIIbb3 in a low-afﬁnity
state. Correspondingly, the polymorphism Arg633His can
enhancetheseparationofdomains.Interferingwithinter-
domain interactions can increase protein ﬂexibility and
initiate the extension of the integrin.46 Another example is
HPA-1b where a Pro33 in b3 subunit has been reported to
cause hypercoagulability effects47 due to increased aggre-
gability,48 different sensitivity to agonists,49 or enhance-
ment of outside-in signaling.50 It is possible that the
polymorphism might partially mimic the activated con-
formation. Our analyses show that both Arg633 and Leu33
inb3arelocatedclosetotheinterfacewithotherdomains,
implying that the substitutions might affect interdomain
rearrangements. Taken together, these data suggest that
althoughtheresiduesthatformtheHPAsareprobablynot
involved in stabilizing the three-dimensional fold, their
surface location might shape the rigidity of the protein,
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the protein more prone to activation.
In conclusion, our analyses provide a unique per-
spective to the molecular basis of amino acid substitu-
tions leading to the formation of epitopes for auto-/
alloantibodies. The HPAs involve SNPs at evolutionary
variable positions located on the protein surface. These
polymorphisms do not cause diseases but lead to immu-
nologic disorders. Interestingly, some HPAs might also
affect the activation process of the protein. The integrins
form hetrodimers, whereas each subunit comprises mul-
tiple domains. This allows a regulation mechanism that
involves multiple conformations of the protein on the cell
surface. Our analyses show that some HPAs involve sub-
stitutions at positions located at the interface between
domains and thereby might affect interdomain rearrange-
ment and the activation dynamics.
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